Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Allergy Therapeutics ( (GB:AGY) ) just unveiled an update.
Allergy Therapeutics reported stable financial performance for the year ending June 2025, with revenue remaining flat at £55.0m due to the transition to fully licensed products in Germany. The company strengthened its financial position through strategic investments, securing a new £50m shareholder loan facility, and exploring a dual primary listing in Hong Kong. Progress in R&D was highlighted by advancements in the Grass MATA MPL and VLP Peanut PROTECT trials, positioning the company for future growth and increased market presence.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The stock score is primarily impacted by the company’s weak financial performance and valuation concerns, which are somewhat balanced by positive technical indicators and promising corporate events. The financial instability remains a significant risk, although recent product developments offer potential upside.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is a fully integrated commercial biotechnology company specializing in allergy immunotherapies. The company focuses on developing and commercializing products for allergy treatment, with a significant market presence in Europe and ambitions to expand in Asia.
Average Trading Volume: 395,577
Technical Sentiment Signal: Buy
Current Market Cap: £657.1M
Learn more about AGY stock on TipRanks’ Stock Analysis page.